VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform

Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics, supporting the FDA’s push toward more predictive, human-relevant testing and reduced reliance on animal models.

Victoria, BC and Vancouver, BC, May 13, 2026. VoxCell BioInnovation Inc. (“VoxCell”), a developer of bioprinted vascularized human tissue models for preclinical drug development, and adMare BioInnovations (“adMare”), Canada’s life sciences company creation engine, today announced a research partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell’s human-relevant vascularized cancer tissue models.

VoxCell’s platform brings together human tumor, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct. The result is a human-like system that recapitulates antibody delivery, immune activity, and downstream tumor biology, with quantitative readouts across efficacy and safety endpoints that legacy in vitro and in vivo models struggle to deliver.

The partnership comes as the U.S. Food and Drug Administration advances its plan to significantly reduce animal testing for monoclonal antibodies and other biologics, expanding the use of New Approach Methodologies (NAMs), including human-relevant 3D tissue platforms, organ-on-chip systems, and AI-based models, to improve preclinical translation rates.

“adMare’s mission is to translate breakthrough scientific discoveries  into strong, investable Canadian life science companies and new therapies that reach patients,” said Matthew J. Carlyle, President and CEO of adMare BioInnovations. “That requires more than capital – it requires hands-on company building support and access to the right commercial R&D tools early on. By integrating VoxCell’s human-relevant vascularized tissue platform into our scientific and commercial validation process we can generate stronger preclinical safety and efficacy evidence sooner. This helps us de‑risk innovation, create long‑term value, and turn promising science into scalable, globally competitive Canadian companies.”

VoxCell’s platform is built on a high-resolution bioprinting process that produces perfusable vascular networks inside human-like tissue, addressing a long-standing gap in 3D cell culture. The models are designed to support large biologics, immune-modulating therapies, and other modalities where antibody transport, endothelial barrier function, and immune complexity drive in vivo behavior.

“Animal models often miss the biology that determines whether a human drug works,” said Dr. Karolina Valente, Chief Executive Officer and Chief Scientific Officer of VoxCell. “Our vascularized tissues bring perfusion, endothelial barriers, immune cells, and stroma into one human-relevant system. Working with adMare on a novel biologic is exactly the use case the FDA had in mind when it called for more predictive, human-relevant tools. The result is better decisions earlier, and fewer animals used along the way.”

Data generated under the collaboration will inform adMare’s program development and contribute to a broader effort to qualify VoxCell’s vascularized cancer tissue model as a reference NAM for immuno-oncology biologics.

- 30 -

About VoxCell BioInnovation

VoxCell accelerates drug development with physiologically relevant human-like tissue models. The company’s high-resolution bioprinting platform produces perfusable vascular networks inside immune-competent 3D tissues, giving pharma and biotech partners a more predictive view of efficacy and safety in the preclinical setting. Vascular by design. Human by nature. Learn more at voxcellbio.com.

About adMare BioInnovations

adMare BioInnovations is Canada’s life sciences company creation engine, focused on building and scaling strong, investable companies. Our unique model identifies breakthrough innovations addressing unmet patient needs and supports early company creation and growth through pre-seed investment, commercial R&D and IP and business development expertise. This approach helps establish the scientific validation, value, and operating foundations needed to build globally competitive Canadian life science companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital, achieved a combined value of $5.8 billion, and created approximately 1,000 jobs.  

adMare also provides more than 200,000 square feet of turnkey lab facilities and delivers industry-ready talent and executive leadership development programs to help Canadian life science companies scale and succeed. Learn more at www.admarebio.com 

Media Contact

Graham Craig
Chief Commercial Officer
VoxVell BioInnovation
gcraig@voxcellbio.com
(672) 974-8850

Bethany Moir  
Senior Director, Public Affairs 
adMare BioInnovations  
bmoir@admarebio.com